Inactivation	O
of	O
Cancer	B:C1516197
Mutations	I:C1516197
Utilizing	O
CRISPR	O
/	I:C3658355
Cas9	I:C3658355

Inactivation	O
of	O
Cancer	O
Mutations	I:C1516197
Utilizing	O
CRISPR	B:C3658355
/	I:C3658355
Cas9	I:C3658355

Although	O
whole	B:C3640076
-	I:C3640076
genome	I:C3640076
sequencing	I:C3640076
has	O
uncovered	O
a	O
large	O
number	O
of	O
mutations	O
that	O
drive	O
tumorigenesis	O
,	O
functional	O
ratification	O
for	O
most	O
mutations	O
remains	O
sparse	O
.	O

Although	O
whole	O
-	I:C3640076
genome	I:C3640076
sequencing	I:C3640076
has	O
uncovered	O
a	O
large	O
number	O
of	O
mutations	B:C0026882
that	O
drive	O
tumorigenesis	O
,	O
functional	O
ratification	O
for	O
most	O
mutations	O
remains	O
sparse	O
.	O

Although	O
whole	O
-	I:C3640076
genome	I:C3640076
sequencing	I:C3640076
has	O
uncovered	O
a	O
large	O
number	O
of	O
mutations	O
that	O
drive	O
tumorigenesis	B:C0596263
,	O
functional	O
ratification	O
for	O
most	O
mutations	O
remains	O
sparse	O
.	O

Although	O
whole	O
-	I:C3640076
genome	I:C3640076
sequencing	I:C3640076
has	O
uncovered	O
a	O
large	O
number	O
of	O
mutations	O
that	O
drive	O
tumorigenesis	O
,	O
functional	O
ratification	O
for	O
most	O
mutations	B:C0026882
remains	O
sparse	O
.	O

Here	O
,	O
we	O
present	O
an	O
approach	O
to	O
test	O
functional	O
relevance	O
of	O
tumor	B:C1516197
mutations	I:C1516197
employing	O
CRISPR	O
/	I:C3658355
Cas9	I:C3658355
.	O

Here	O
,	O
we	O
present	O
an	O
approach	O
to	O
test	O
functional	O
relevance	O
of	O
tumor	O
mutations	I:C1516197
employing	O
CRISPR	B:C3658355
/	I:C3658355
Cas9	I:C3658355
.	O

Combining	O
comprehensive	O
sgRNA	B:C0082774
design	O
and	O
an	O
efficient	O
reporter	O
assay	O
to	O
nominate	O
efficient	O
and	O
selective	O
sgRNAs	O
,	O
we	O
establish	O
a	O
pipeline	O
to	O
dissect	O
roles	O
of	O
cancer	O
mutations	I:C1516197
with	O
potential	O
applicability	O
to	O
personalized	O
medicine	I:C2718059
and	O
future	O
therapeutic	O
use	O
.	O

Combining	O
comprehensive	O
sgRNA	O
design	O
and	O
an	O
efficient	O
reporter	O
assay	B:C1510438
to	O
nominate	O
efficient	O
and	O
selective	O
sgRNAs	O
,	O
we	O
establish	O
a	O
pipeline	O
to	O
dissect	O
roles	O
of	O
cancer	O
mutations	I:C1516197
with	O
potential	O
applicability	O
to	O
personalized	O
medicine	I:C2718059
and	O
future	O
therapeutic	O
use	O
.	O

Combining	O
comprehensive	O
sgRNA	O
design	O
and	O
an	O
efficient	O
reporter	O
assay	O
to	O
nominate	O
efficient	O
and	O
selective	O
sgRNAs	B:C0082774
,	O
we	O
establish	O
a	O
pipeline	O
to	O
dissect	O
roles	O
of	O
cancer	O
mutations	I:C1516197
with	O
potential	O
applicability	O
to	O
personalized	O
medicine	I:C2718059
and	O
future	O
therapeutic	O
use	O
.	O

Combining	O
comprehensive	O
sgRNA	O
design	O
and	O
an	O
efficient	O
reporter	O
assay	O
to	O
nominate	O
efficient	O
and	O
selective	O
sgRNAs	O
,	O
we	O
establish	O
a	O
pipeline	O
to	O
dissect	O
roles	O
of	O
cancer	B:C1516197
mutations	I:C1516197
with	O
potential	O
applicability	O
to	O
personalized	O
medicine	I:C2718059
and	O
future	O
therapeutic	O
use	O
.	O

Combining	O
comprehensive	O
sgRNA	O
design	O
and	O
an	O
efficient	O
reporter	O
assay	O
to	O
nominate	O
efficient	O
and	O
selective	O
sgRNAs	O
,	O
we	O
establish	O
a	O
pipeline	O
to	O
dissect	O
roles	O
of	O
cancer	O
mutations	I:C1516197
with	O
potential	O
applicability	O
to	O
personalized	B:C2718059
medicine	I:C2718059
and	O
future	O
therapeutic	O
use	O
.	O

